Novartis Ag (NVS) Receivables - Net (2009 - 2025)
Novartis Ag recorded quarterly Receivables - Net of $8.9 billion in Q4 2025, down 1.31% quarter-over-quarter from $9.1 billion in Q2 2025, and up 20.4% year-over-year from $7.4 billion in Q4 2024.
Novartis Ag's Receivables - Net history runs 14 years deep, the most recent figure standing at $8.9 billion for Q4 2025.
- In Q4 2025, Receivables - Net rose 20.4% year-over-year to $8.9 billion; the TTM figure through Dec 2025 stood at $8.9 billion (up 20.4% YoY), while the FY2025 annual figure was $8.9 billion, up 20.4% from the prior year.
- Receivables - Net came in at $8.9 billion for Q4 2025 at Novartis Ag, down from $9.1 billion in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $9.2 billion in Q2 2023 to a low of $7.1 billion in Q4 2023.
- A 5-year average of $8.3 billion and a median of $8.3 billion in 2021 frame the typical range for Receivables - Net.
- Across the five-year window, Receivables - Net declined 11.89% in 2023 and increased 20.4% in 2025, its largest moves.
- Novartis Ag's Receivables - Net stood at $8.0 billion in 2021, then increased by 0.76% to $8.1 billion in 2022, then dropped by 11.89% to $7.1 billion in 2023, then climbed by 4.45% to $7.4 billion in 2024, then rose by 20.4% to $8.9 billion in 2025.
- According to Business Quant data, Receivables - Net over the past three periods registered $8.9 billion, $9.1 billion, and $7.4 billion for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.94 Bn |
| Dec 31, 2025 | 8.94 Bn |
| Jun 30, 2025 | 9.06 Bn |
| Jun 30, 2025 | 9.06 Bn |
| Dec 31, 2024 | 7.42 Bn |
| Dec 31, 2024 | 7.42 Bn |
| Jun 30, 2024 | 8.23 Bn |
| Jun 30, 2024 | 8.23 Bn |
| Dec 31, 2023 | 7.11 Bn |
| Dec 31, 2023 | 7.11 Bn |
| Jun 30, 2023 | 9.20 Bn |
| Jun 30, 2023 | 9.20 Bn |
| Dec 31, 2022 | 8.07 Bn |
| Dec 31, 2022 | 8.07 Bn |
| Jun 30, 2022 | 8.64 Bn |
| Jun 30, 2022 | 8.64 Bn |
| Dec 31, 2021 | 8.01 Bn |
| Dec 31, 2021 | 8.01 Bn |
| Jun 30, 2021 | 8.40 Bn |
| Jun 30, 2021 | 8.40 Bn |
| Dec 31, 2020 | 8.22 Bn |
| Dec 31, 2020 | 8.22 Bn |
| Jun 30, 2020 | 7.64 Bn |
| Jun 30, 2020 | 7.64 Bn |
| Dec 31, 2019 | 8.30 Bn |
| Dec 31, 2019 | 8.30 Bn |
| Jun 30, 2019 | 4.00 Mn |
| Jun 30, 2019 | 4.00 Mn |
| Dec 31, 2018 | 8.73 Bn |
| Dec 31, 2018 | 8.73 Bn |
| Jun 30, 2018 | 8.80 Bn |
| Jun 30, 2018 | 8.80 Bn |
| Dec 31, 2017 | -190.00 Mn |
| Dec 31, 2017 | -190.00 Mn |
| Dec 31, 2016 | -162.00 Mn |
| Dec 31, 2016 | -162.00 Mn |
| Dec 31, 2015 | -142.00 Mn |
| Dec 31, 2015 | -142.00 Mn |
| Jun 30, 2015 | 122.00 |
| Jun 30, 2015 | 122.00 |
| Mar 31, 2015 | 83.00 |
| Mar 31, 2015 | 83.00 |
| Dec 31, 2013 | 159.00 |
| Dec 31, 2013 | 159.00 |
| Mar 31, 2010 | 7,773.00 |
| Mar 31, 2010 | 7,773.00 |
| Dec 31, 2009 | 8,310.00 |
| Dec 31, 2009 | 8,310.00 |
| Sep 30, 2009 | 7,817.00 |
| Sep 30, 2009 | 7,817.00 |
| Jun 30, 2009 | 7,167.00 |
| Jun 30, 2009 | 7,167.00 |
| Mar 31, 2009 | 6,751.00 |
| Mar 31, 2009 | 6,751.00 |